Genopharm collapse throws doubt on product recalls and court cases
This article was originally published in Scrip
Executive Summary
France's regulatory body Afssaps has delayed a recall of all products marketed by Laboratoires Genopharm after the rare diseases firm was unexpectedly dissolved by its owners. Genopharm's operations and those of its French affiliate Alkopharm, to which its assets have been transferred, had been suspended in December pending a resolution of pharmacovigilance and other regulatory issues, and the phased recalls were due to start on 2 January.